2011 Annual Meeting Brochure
2012 Annual Meeting in Tampa, FL, April 29-May 2
Making Sense of Antidepressants: An Evidence-Based Approach to the Controversies
The controversies surrounding the use of antidepressants in the treatment of depressive disorders have rocked the world of psychiatry. From black box warnings to heated debates about efficacy in leading medical journals, this topic is sure to be timely and thought provoking. Nassir Ghaemi, MD, MPH will present Making Sense of Antidepressants: An Evidence-Based Approach to the Controversies on Sunday. Dr. Ghaemi is a world renowned leader in the treatment of mood disorders and author of A First-Rate Madness: Uncovering the Links Between Leadership and Mental Illness. After his presentation, you will have the chance to meet with Dr. Ghaemi and purchase a signed copy of this provocative book! Right now you can watch an interview with Dr. Ghaemi on The Colbert Report.
Product Theaters
Promotional product theaters are new to the CPNP Annual Meeting with two being offered in 2011. These product theaters are scientific programs developed for educational purposes. They allow for presentation of new research findings on products, showcasing of product details, demonstrations and highlights of new products. These sessions are promotional and are not eligible for continuing education credits. Attendance at the product theaters is first-come, first-served and seating is limited. A refreshment break or meal is provided at each event.
Monday, May 2: 4:45-6:15 p.m.
Personalizing Antidepressant Therapy: Clinical Evidence for Adjunctive L-methylfolate
Clinical pharmacists working as specialists in neuropsychopharmacology impact selection of antidepressant therapies. These influential therapeutic decisions can optimize treatment outcomes in patients with major depressive disorder. Personalizing antidepressant therapy with a trimonoamine modulator that targets underlying disease pathology is an emerging therapeutic option. Please join us to explore controlled evidence for improving patient outcomes in depression with a novel therapeutic agent.
Faculty
Stephen Stahl, MD, PhD
Department of Psychiatry
University of Californa
San Diego, CA
Department of Psychiatry
University of Cambridge, UK
Tracy Hunter, Pharm D, PhD
Tentative Agenda
| 4:45-5:15 PM | Registration/Seating and Break Function |
|---|---|
| 5:15-6:15 PM | Personalizing Antidepressant Therapy: Clinical Evidence for Adjunctive L-methylfolate |
Registration
Registration will be accepted on a first-come, first-served basis onsite; therefore, pre-registration is not required. Doors will open at 4:45 PM. There is no registration fee to attend this activity.
Offered By
Tuesday, May 3: 12:00-1:30 p.m.
A New Atypical Antipsychotic Agent for the Treatment of Schizophrenia
Faculty
Larry Ereshefsky, PharmD, FCCP, BCPP
Vice President, Psychiatry Therapeutic Expert
Parexel
Hollywood, CA
Tentative Agenda
| 12:00-12:30 PM | Registration/Seating and Meal Function |
|---|---|
| 12:30-1:30 PM | A New Atypical Antipsychotic Agent for the Treatment of Schizophrenia |
Registration
Registration will be accepted on a first-come, first-served basis onsite; therefore, pre-registration is not required. Doors will open at 11:45 AM. There is no registration fee to attend this activity.
Offered By
Offered by Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.)